The Latest Cardiac and Vascular News
VEMERIX analysis finds the single-use consumable, not the capital laser console, is the value engine in the USD 1.4–1.6 billion varicose-vein device market — with Asia-Pacific growing fastest at up to 8.4% CAGR. WEIHAI, China, June 29, 2026 /PRNewswire/ — VEMERIX, the international…
TEMPE, Ariz., June 25, 2026 (GLOBE NEWSWIRE) — Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational Nectero EAST® System. The study met safety endpoints, and AAA growth rates were significantly lower than expected through two years post-treatment. At the 2026 Vascular Annual Meeting (VAM) held in Boston last week, the impact of PGG treatment on proximal neck dynamics was presented by Dr. Matthew Eagleton, Chief, Mass General Brigham Vascular and Endovascular Surgery.
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
AI-Powered Triage Software Helps Radiologists Identify and Prioritize Peripheral Vascular Disease in Lower-Extremity CT Imaging AI-Powered Triage Software Helps Radiologists Identify and Prioritize Peripheral Vascular Disease in Lower-Extremity CT Imaging
USP Class VI, ISO 10993 biocompatibility evaluation, and ISO 13485:2016 quality system certification, manufactured at an FDA-registered facility DONGGUAN, China, June 16, 2026 /PRNewswire/ — Dongguan Ruixiang Precision Silicone Products Co., Ltd. (Ruixiang Silicone) has released a…
– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery’s Vascular Annual Meeting in Boston –
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
MIAMI, June 08, 2026 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (“NPS”), for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization (“TCAR”) procedures. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio.
International gathering of more than 1,400 vascular specialists will feature the latest data on limb-threatening diseases, novel technology and integration of specialty within larger healthcare system BOSTON, MA, MAY 27, 2026 – The Society for Vascular Surgery’s Vascular Annual Meeting (VAM) will commence on Wednesday, June 10, 2026, uniting the greatest […]
PROVIDENCE, R.I., May 27, 2026 /PRNewswire/ — In a new feasibility study published in Annals of Family Medicine, general practitioners (GPs) in China were able to accurately detect carotid artery plaque — an indicator of cardiovascular disease — in high-risk patients using an AI-assisted…
